

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A composition comprising an isolated and purified peptide defined by an amino acid sequence selected from the group consisting of ~~SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 14, and SEQ ID NO: 15 and SEQ ID NO: 16~~ and a portion thereof, wherein said portion is approximately five amino acids in length.
2. (Previously presented) The composition of Claim 1, wherein said peptide is suitable for the reduction of C5a binding to neutrophils.
3. (Cancelled) Antibodies produced from the peptide of claim 1.
4. (Cancelled) A method, comprising:
 - a) providing;
 - i) neutrophils,
 - ii) a purified peptide having an amino acid sequence selected from the group of SEQ ID NO: 14 and SEQ ID NO: 15, and portions thereof;
and
 - b) mixing said neutrophils with said peptide under conditions such that the ability of said neutrophils to bind full-length human C5a peptide is reduced.
5. (Cancelled) The method of Claim 4, wherein said neutrophils are human neutrophils.
6. (Cancelled) The method of Claim 4, wherein said neutrophils are murine neutrophils.
7. (Cancelled) The method of Claim 4, wherein said neutrophils are rat neutrophils.
8. (Cancelled) A method, comprising:
 - a) providing;
 - i) neutrophils,

- ii) a purified peptide having an amino acid sequence selected from the group of SEQ ID NO: 14 and SEQ ID NO: 15, and portions thereof;
and
 - b) treating said neutrophils with said peptide under such conditions that C5a activation of said neutrophils is inhibited.
9. (Cancelled) The method of Claim 8, wherein said neutrophils are human neutrophils.
10. (Cancelled) The method of Claim 8, wherein said neutrophils are murine neutrophils.
11. (Cancelled) The method of Claim 8, wherein said neutrophils are rat neutrophils.
12. (Cancelled) A composition comprising:
- a) an isolated and purified C-terminal truncated C5a peptide of a species, said peptide is between approximately five and fifty amino acids in length and said species is selected from a group consisting of human, rat and bovine and,
 - b) adjuvant or buffered saline.
13. (Currently Amended) The composition of Claim 12, further comprising adjuvant
~~wherein said C-terminal truncated C5a peptide is selected from the group consisting of~~
~~SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO~~
~~16.~~
14. (Currently Amended) The composition of Claim 13, wherein said adjuvant is selected from the group consisting of agar beads, aluminum hydroxide, aluminum phosphate, incomplete Freund's, Quail A, Gerbu and bacterin.
15. (Cancelled) The composition of Claim 12, wherein said peptide is suitable for the reduction of C5a binding to neutrophils.

16. (Cancelled) A composition comprising:
 - a) an isolated and purified variant C-terminal truncated C5a peptide that is between five and fifty amino acids in length, and;
 - b) adjuvant or buffered saline.
17. (Cancelled) The compositions of Claim 16, wherein said variant C-terminal truncated C5a peptide is selected from the group consisting of SEQ ID NOS: 20-74.
18. (Cancelled) The composition of Claim 16, wherein said adjuvant is selected from the group consisting of agar beads, aluminum hydroxide, aluminum phosphate, incomplete Freund's, Quail A, Gerbu and bacterin.
19. (Cancelled) The composition of Claim 16, wherein said peptide is suitable for reduction of C5a binding to neutrophils.